Fatty acid amide hydrolase

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 29, 2022
Health, Pharmaceutical, News, Fatty acid amide hydrolase, Precision medicine, FAAH, Industry, Book, Therapy, Dietary supplement, Pharmaceutical industry, Fine chemical

The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022" report by the publisher offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Fatty Acid Amide Hydrolase (FAAH) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Drug Pipeline Market Research Report 2022 Featuring Johnson & Johnson, Renovis, Vernalis, Pfizer, Mayssen-Cilag, sanofi-aventis, & Advinus Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 9, 2022
Health, Pharmaceutical, FAAH, Fatty acid amide hydrolase, Therapy, Pharmaceutical industry, Fine chemical

The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development.
  • The report assesses the active Fatty Acid Amide Hydrolase (FAAH) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
  • Offers detailed therapeutic product profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

Retrieved on: 
Tuesday, May 11, 2021
Biotechnology, Health, Clinical trials, Medical Supplies, Neurology, Remyelination, Fatty acid amide hydrolase

Peripheral blockade of FAAH activity further improves selective brain delivery of Autobahn\xe2\x80\x99s compounds and enhances the ability to tailor a drug\xe2\x80\x99s biodistribution to match the pathophysiology of various disorders.

Key Points: 
  • Peripheral blockade of FAAH activity further improves selective brain delivery of Autobahn\xe2\x80\x99s compounds and enhances the ability to tailor a drug\xe2\x80\x99s biodistribution to match the pathophysiology of various disorders.
  • \xe2\x80\x9cWhile there have been numerous advancements in the care of patients with MS, we believe there is a tremendous need for new therapeutic agents targeting remyelination.
  • Autobahn has acquired global intellectual property, development and regulatory rights to ASP3652.\nAutobahn Therapeutics is focused on restoring hope for people affected by CNS disorders.
  • Autobahn is leveraging its brain-targeting chemistry platform to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules.

Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 27, 2019
Health, Oncology, Pharmaceutical, Cannabinoids, Chemical compounds, Chemistry, Drugs, Enzyme inhibitors, Fatty acid amide hydrolase, Endocannabinoids, Carbamates, Endocannabinoid enhancer, MK-4409

The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine